• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Viking Therapeutics Inc.

    4/1/26 4:15:28 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VKTX alert in real time by email
    DEFA14A 1 vktx-2026-04-01-defa14a_.htm DEFA14A DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.)

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12


    VIKING THERAPEUTICS, INC
    .

    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     


    img16950487_0.jpg

    Important Notice of Availability of Proxy Materials for the Stockholder Meeting of VIKING THERAPEUTICS, INC. To Be Held On: May 19, 2026, at 8:00 a.m. Pacific Time virtually at edge.media-server.com/mmc/p/cimrmdwx (password: viking2026) COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before 05/05/26. Please visit www.astproxyportal.com/ast/20061/, where the following materials are available for view: • Notice of Annual Meeting of Stockholders • Proxy Statement • Form of Electronic Proxy Card • Annual Report on Form 10-K TO REQUEST MATERIAL: TELEPHONE: 1-888-Proxy-NA (1-888-776-9962) or +1-201-299-6210 (worldwide) E-MAIL: help@equiniti.com WEBSITE: us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials TO VOTE: ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 p.m. Eastern Time the day before the meeting date. VIRTUALLY AT THE MEETING: The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet, please visit edge.media-server.com/mmc/p/cimrmdwx (password: viking2026) and be sure to have your control number available. TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call. MAIL: You may request a card by following the instructions above. 1. ELECTION OF DIRECTOR NOMINEES FOR CLASS II (term to expire 2. TO RATIFY THE SELECTION OF CBIZ CPAS P.C. AS THE COMPANY'S in 2029): INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026. NOMINEES: J. Matthew Singleton S. Kathryn Rouan, Ph.D. 3. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS. THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR ALL NOMINEES" IN PROPOSAL 1 AND "FOR" PROPOSALS 2 AND 3. Please note that you cannot use this notice to vote by mail.


    Get the next $VKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VKTX

    DatePrice TargetRatingAnalyst
    5/28/2026$89.00Buy
    Lake Street
    5/27/2026$83.00Buy
    Truist
    3/26/2026Peer Perform
    Wolfe Research
    10/29/2025$106.00Buy
    Canaccord Genuity
    4/29/2025$104.00Overweight
    Cantor Fitzgerald
    4/8/2025$30.00Neutral
    Goldman
    2/13/2025$102.00Sector Outperform
    Scotiabank
    2/7/2025$38.00Neutral
    Citigroup
    More analyst ratings

    $VKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/8/25 7:05:30 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/2/25 6:29:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viking Therapeutics to Participate at Upcoming Investor Conferences

    SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company's participation are as follows:William Blair 46th Annual Growth Stock ConferenceDetails: Viking management will deliver a corporate presentation, followed by a breakout session, and partic

    5/21/26 7:05:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

    AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE:S

    5/13/26 8:30:00 AM ET
    $ABBV
    $ALT
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

    Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second poster at the conferenceSAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional data from its Phase 2 VENTURE-Oral

    5/12/26 7:05:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    SEC Filings

    View All

    Viking Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Viking Therapeutics, Inc. (0001607678) (Filer)

    5/26/26 4:48:01 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Viking Therapeutics Inc.

    10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)

    4/29/26 9:50:35 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Viking Therapeutics, Inc. (0001607678) (Filer)

    4/29/26 4:05:17 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Chen Hubert C

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    6/3/26 7:44:43 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chen Hubert C

    3 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    6/3/26 7:43:52 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Viking Therapeutics Inc.

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    3/10/26 6:20:39 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Viking Therapeutics with a new price target

    Lake Street initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $89.00

    5/28/26 8:39:18 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Viking Therapeutics with a new price target

    Truist resumed coverage of Viking Therapeutics with a rating of Buy and set a new price target of $83.00

    5/27/26 8:17:04 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Viking Therapeutics

    Wolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Financials

    Live finance-specific insights

    View All

    Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled ---- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 ---- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 ---- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 ---- Strong Quarter-End Cash Position of $603 Million --SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial resu

    4/29/26 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

    Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We

    4/22/26 4:35:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/12/24 5:54:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/4/24 1:54:45 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care